34th Annual CTRC-AACR San Antonio Breast Cancer Symposium – December 6-10, 2011

• Poster: "Promising The BEACON Study (BrEAst Cancer Outcomes with NKTR-102): A Phase 3 Open-Label, Randomized, Multicenter Study of NKTR-102 Versus Treatment of Physician's Choice (TPC) in Patients (pts) with Locally Recurrent or Metastatic Breast Cancer (MBC) Previously Treated with an Anthracycline, a Taxane, and Capecitabine (ATC)." Ahmad Awada, M.D., et al.

2001 Chemotherapy Foundation Symposium – November 8-13, 2011

• Presentation: "Promising Activity of NKTR-102 in Patients with Metastatic Breast Cancer and Platinum Resistant/Refractory Ovarian Cancer." Edith Perez, M.D., et al..

2011 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference - November 12 - 16, 2011

• Abstract # C209: Strong Synergistic Activity of NKTR-102 - Pegylated Liposomal Doxorubicin (PLD) Combination Therapy in a Nonclinical Model of Platinum Resistant A2780 Human Ovarian Cancer

2011 American Society of Clinical Oncology Annual Meeting - June 3-6, 2011

• Press Release: NKTR-102 Shows High Response Rate and Sustained Duration of Response in Women with Platinum-Resistant/Refractory Ovarian Cancer Previously Treated with Doxil®

• Press Release: NKTR-102 Demonstrates Sustained Clinical Benefit in 46% of Patients with Metastatic Breast Cancer in Data Presented at 2011 American Society of Clinical Oncology Annual Meeting

• Abstract 1034 – Poster #24: Significant Antitumor Activity in a Randomized Phase 2 Study Comparing Two Schedules of NKTR-102 in Patients With Pre-Treated Metastatic Breast Cancer (June 2011)

• Abstract 5047 – Poster #15C: "Promising Activity of NKTR-102 in Women with Platinum Resistant/Refractory Ovarian Cancer and Failure on Pegylated Liposomal Doxorubicin (PLD)"

• Abstract 2598, Poster 8E: "Population Pharmacokinetics of NKTR-102, a Topoisomerase I Inhibitor-Polymer Conjugate in Patients With Advanced Solid Tumors"

33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium - December 12, 2010

• Press Release: NKTR-102 Demonstrates Significant Efficacy as Single-Agent in Second- or Third-Line Treatment in Metastatic Breast Cancer Patients
  Phase 2 Data Presented at the 33rd Annual CTRC-AACR San Antonio Breast Cancer Symposium

• Poster: "Significant Efficacy in a Phase 2 Study of NKTR-102, a Novel Polymer Conjugate of Irinotecan, in Patients With Pre-Treated Metastatic Breast Cancer (MBC)" (December 2010)

ESMO Conference: 12th World Congress on Gastrointestinal Cancers

• Poster # P-0025: Activity of NKTR-102 in Nonclinical Models of Gastrointestinal Cancers

2010 ASCO Meeting

• Presentation: "Phase II Study of NKTR-102 in Women with Platinum Resistant/Refractory Ovarian Cancer"

• Abstract 5013: Phase II Study of NKTR-102 in Women with Platinum Resistant/Refractory Ovarian Cancer

Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer - January 12, 2010

• Press Release: Nektar Therapeutics Announces Positive Topline Results for NKTR-102 From First Stage of Phase 2 Study in Platinum-Resistant Ovarian Cancer

Data Presentation from ECCO15/ESMO 34 2009 Multidisciplinary Conference - September 22, 2009

• Poster #161: NKTR-102 Demonstrates Nonclinical and Phase 1 Clinical Anti-tumor Activity in Ovarian Cancer

Data Presentation from 2008 EORTC-NCI-AACR Symposium - October 23, 2008

• Press Release: Significant Anti-Tumor Activity and Extended Half-Life of NKTR-102 (PEG-irinotecan) Highlighted in Phase 1 Data Presented at EORTC-NCI-AACR Symposium

• Poster #595: First Phase I Trial of NKTR-102 (PEG-irinotecan) Reveals Early Evidence of Broad Anti-Tumor Activity in Three Different Schedules - Authors: D.D. Von Hoff, G.S. Jameson, M.J. Borad, L.S. Rosen, J. Utz, M. Basche, C. Alemany, S. Dhar, L. Acosta, T. Barker, J. Walling, J.T. Hamm.

Data presentation from ASCO Annual Meeting - June 2, 2008

• Investigator Presentation to Investors: Phase 1 Data Discussed at Investor Event by Dr. Daniel Von Hoff, lead investigator for NKTR-102

• Press Release: New Positive Data Announced for NKTR-102 (PEG-irinotecan), Highlights Promise of Nektar's Innovative Small Molecule PEG-Oncolytics

Data Presentations from AACR 2008 - April 14, 2008

• Press Release: Additive Anti-Tumor Activity of NKTR-102 in Combination With Bevacizumab Highlighted in Positive Preclinical Data Presented at AACR Meeting

• Poster #766: Enhanced anti-tumor activity of NKTR-102, a novel PEGylated-irinotecan, when administered in combination with bevacizumab in a mouse model of human colorectal tumors

• Poster #5741: NKTR-102, a novel PEGylated-irinotecan, has an enhanced pharmacokinetic profile with reduced gastrointestinal and hematopoietic toxicity compared to irinotecan with repeat dosing in dogs

• Poster #5742: NKTR-102, a novel PEGylated-irinotecan, has a superior acute safety, tolerability, and pharmacokinetic profile compared to irinotecan in rats and dogs

Data Presentations from 2007 AACR-NCI-EORTC International Conference - October 25, 2007

• Press Release: NKTR-102 (PEG-Irinotecan) Demonstrates Significant Tumor Growth Inhibition in Multiple Preclinical Tumor Models

• Poster #C10: NKTR-102, a novel polyethylene glycol conjugate of irinotecan, has improved anti-tumor activity in three mouse xenograft models

• Poster #C157: NKTR-102, a novel PEGylated-irinotecan conjugate, results in sustained tumor growth inhibition in mouse models of human colorectal and lung tumors that is associated with increased and sustained tumor SN38 exposure

Data Presentations from ECCO 14 Conference - September 27, 2007

• Press Release: NKTR-102 (PEG-Irinotecan) Demonstrates Significant Anti-Tumor Activity and Improved Time-Concentration Profile in Preclinical Studies Presented at ECCO 14

• Poster #722: Anti-tumor activity and pharmacokinetics of NKTR-102, a novel PEGylated-irinotecan conjugate, in irinotecan-resistant colorectal tumors implanted in mice - Presented at ECCO 14 (14th Annual European Cancer Conference)

• Poster #727: NKTR-102, a novel PEGylated-irinotecan conjugate, demonstrates improved pharmacokinetics with sustained exposure of irinotecan and its active metabolite-Presented at ECCO 14 (14th Annual European Cancer Conference)